Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT02829372 |
| Title | Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers (GBR 1302-101) |
| Acronym | GBR 1302-101 |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Glenmark Pharmaceuticals S.A. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | DEU |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Glenmark Investigational Site 204 | Fairway | Kansas | 66205 | United States | Details | |
| Glenmark Investigational Site 209 | Detroit | Michigan | 48201 | United States | Details | |
| Glenmark Investigational Site 201 | Dallas | Texas | 75230 | United States | Details | |
| Glenmark Investigational Site 203 | Salt Lake City | Utah | 84112 | United States | Details | |
| Glenmark Investigational Site 103 | Berlin | 10117 | Germany | Details | ||
| Glenmark Investigational Site 102 | Cologne | 50670 | Germany | Details | ||
| Glenmark Investigational Site 101 | Dresden | 01307 | Germany | Details | ||
| Glenmark Investigational Site 104 | Mainz | 55131 | Germany | Details |